ArticleThe American journal of case reports2026
Neonatal-Onset Refractory Thrombocytopenia and Anemia Associated With a Homozygous In-Frame NFE2 Duplication.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND NFE2 encodes p45/NF-E2, a transcriptional regulator of megakaryocyte maturation and platelet production. However, germline NFE2-associated cytopenias are rare; consequently, the clinical spectrum is incompletely defined. CASE REPORT We report the case of a preterm neonate born to consanguineous parents who developed day-1-onset bicytopenia with transfusion-dependent thrombocytopenia and intermittent normocytic anemia. Initial evaluation did not support immune-mediated or consumptive causes; moreover, counts were refractory to intravenous immunoglobulin and romiplostim (a thrombopoietin-receptor agonist). Bone marrow examination showed dysmegakaryopoiesis with a paucity of late megakaryocyte forms, supporting defective terminal maturation. Trio sequencing with copy-number analysis identified a homozygous in-frame NFE2 duplication (c.889_900dup; p.Glu297_Arg300dup); both parents were heterozygous carriers, consistent with autosomal-recessive segregation. The duplication lies within the CNC region, adjacent to the basic leucine zipper module implicated in DNA binding and small Maf partner dimerization. Therefore, segregation, domain context, marrow morphology, and TPO-RA non-response implicate NFE2 as the leading etiologic signal, although the variant remains of uncertain significance. CONCLUSIONS This case broadens the emerging NFE2 phenotype to neonatal-onset refractory bicytopenia with dysmegakaryopoiesis and, accordingly, supports a downstream p45/NF-E2 transcriptional maturation defect rather than impaired THPO-MPL signaling. Persistent neonatal cytopenias with dysmegakaryopoiesis and failure of immune-directed therapy and TPO-RA treatment should, therefore, prompt early germline evaluation, ideally trio sequencing with CNV analysis. Finally, targeted functional studies (transactivation, DNA binding, partner interaction) are needed to generate PS3-level evidence and enable definitive reclassification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.